Bing Liang Ph.D.

Partner

Silicon Valley + 1.650.687.4168

Contacto:

Compartir

Dr. Bing Liang advises biotechnology and pharmaceutical companies on procuring and protecting intellectual property, with a focus on biologics and diagnostics. She drives and executes global intellectual property strategies for high‑value innovative medicines and has built strategic patent assets covering CARVYKTI®, SKYRIZI®, BOTOX®, PALYNZIQ®, PADCEV®, VENCLEXTA®, NUPLAZID®, POMALYST®, REVLIMID®, and OTEZLA®.

Chambers recognizes Bing as "excellent to work with" and praises her "superlative work," strategic advice, and technical mastery. Clients quoted by Chambers note that her insights and dedication have been "instrumental" in advancing IP strategies and protecting innovation.

Bing prepares and prosecutes patent applications across antibody therapeutics, immuno‑oncology, cell and gene therapies, genome editing, antisense therapeutics, enzyme replacement therapies, stem cells, and genome sequencing.

She advises on patentability, validity, infringement, and freedom to operate and conducts IP due diligence for venture capital and private equity financings, collaborations, and partnering transactions. She has extensive experience with complex cross‑border deals, navigating multijurisdictional intellectual property landscapes and providing strategic insights that support seamless deal execution.

Her practice also includes post‑grant proceedings before the Patent Trial and Appeal Board (PTAB), including inter partes reviews (IPRs).

Bing's representative clients include AbbVie, Merck, BioMarin Pharmaceutical, Bristol Myers Squibb (Celgene), Legend Biotech, and Astellas, as well as start‑ups, established companies, academic institutions, and investment firms.

Before practicing law, Bing earned a Ph.D. in biomedical sciences from the Mount Sinai School of Medicine of New York University, where she researched chromatin remodeling and genome integrity, identifying critical roles for remodeling complexes in DNA damage repair and telomere length maintenance. She brings deep technical experience in biochemistry, molecular biology, genetics, immunology, and cell biology.

Experiencia

  • Merck develops global patent portfolio related to certain antibodies for treatment of cognitive disordersJones Day is representing Merck & Co., Inc. in the development and prosecution of global patent portfolios related to certain antibodies that are being developed for the treatment and prevention of various cognitive disorders.
  • Merck develops global patent portfolio related to certain bispecific antibodiesJones Day is representing Merck & Co., Inc. in the development and prosecution of a global patent portfolio related to certain bispecific antibodies.
  • Nanjing Legend Biotech establishes global patent portfolio for CAR-T therapeuticsJones Day represents Nanjing Legend Biotech Co., Ltd et al in the development and prosecution of global patent portfolios related to chimeric antigen receptor T cell (CAR-T) and other cellular therapeutics, including CARVYKTI ® and other clinical trial candidates.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Kyowa Hakko Kirin and BioWa successfully enforce patent rights on antibody technologyJones Day, on behalf of Japanese life sciences company Kyowa Hakko Kirin Company, Limited ("KHK") and its wholly-owned U.S. subsidiary, BioWa, successfully settled a patent infringement suit over three of KHK's patents that underlie KHK's award-winning POTELLIGENT® technology capable of producing therapeutic antibodies with dramatically improved potency and efficacy.
  • Kyowa Hakko Kirin defeats competitors in Patent Trial and Appeal Board challenge of patents on antibody technologyOn October 23, 2017, the Patent Trial and Appeal Board ("PTAB") issued a trio of decisions, unanimously declining to institute inter partes review ("IPR") of three patents owned by a Japanese pharmaceutical company represented by Jones Day, Kyowa Hakko Kirin Co., Ltd.
  • NGM develops global patent portfolio for beta-klotho antibodiesJones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for antibodies to beta-klotho for the treatment of diabetes and other metabolic disorders.
  • Scynexis launches public offering of Common StockJones Day led a team that handled the IP diligence for a follow-on public offering of common stock for Scynexis, Inc., a Research Triangle Park, North Carolina, pharmaceutical company committed to the discovery, development, and commercialization of novel anti-infectives.
  • Perlan establishes global patent portfolio for ICAM1 antibodiesJones Day represents Perlan Therapeutics, Inc. in connection with the global patent portfolio for ICAM1 antibodies for the treatment of rhinovirus and other respiratory infections.
  • BioMarin establishes global patent portfolio for PAL technologyOn behalf of BioMarin Pharmaceutical, Inc., Jones Day assisted with global patent portfolio development and prosecution strategies regarding Prokaryotic Phenylalanine Ammonia-Lyase (PAL).
    •

    January 2018 Blog

    Declarations as New Evidence to Overcome § 325(d), PTAB Litigation Blog

    March 2017 Blog

    Including Functional Claim Language Helped Save Pozen’s VIMOVO® Patents, PTAB Litigation Blog

    • April 20, 2019
      The Life Science Patent Landscape and Capital Markets - Updates in China and US, 2019 Chinese Bioscience Association Symposium
    • October 14, 2017
      Opportunities for Biosimilar Companies under the U.S. Legal System, 2017 Chinese Bioscience Association Annual Conference
    • May 8, 2015
      Lecture Presentation, Beijing Foreign Studies University, "Patent Operation in Biotechnological and Pharmaceutical Industries."

    Antes del envío, por favor tenga en cuenta:

    la información contenida en www.jonesday.com es para uso general y no constituye asesoramiento legal. El envío y recepción de este correo electrónico no pretenden crear una relación abogado-cliente. La información que envíe a cualquier persona de nuestra Firma no tendrá carácter confidencial o privilegiado excepto en el caso de que estemos actúando en su representación. Si envía este correo electrónico, confirma que ha leído y comprendido este aviso.